Akers Biosciences Share Discussion Threads

[norbus] 31/12/2014 12:10

mcm

"With these agreements, the Company is now beginning to deliver a more secure long term business base "

By business, he refers to his pension pot ; like Hamas, they take a top slice from the gross take ; AKR had $90 millions in over the years ?

[norbus] 31/12/2014 08:14

mcm
Profit + cash generation create value, not pundit tips usually bought; something fundamental amiss. GLA but I suspect AKR is a benefits affair for Dr Walt, and ever has been so. Tom had energy and ambition; He got UK fund manager on board to execute NASDAQ. You can't get honey out of a wasp. I get the same feeling I had for ACTA now in the resting farm on the way to the corporate resting place.

[rivaldo] 31/12/2014 07:22

The Daily Mail have tweaked their page of tips for 2015 and now include the narrative for AKR's tip as follows - note that the m/cap is only £11m, not the quoted £15m:



"Ian Lyall - Akers Bioscience

If you look at the share price chart of Akers Bioscience you’d think it hadn’t been a particularly clever year for the diagnostics company.

Yet in the past 12 months it has done everything it said it would. The company has developed a rapid test for an allergic reaction to the blood thinner heparin. In the developed Western medical system it offers a cheap and very timely alternative to the current lab tests. In developing economies such as China, where there currently are no lab tests, it will go on to be the gold standard diagnostic.

Indeed the group received its first big order (for £640,000) from the People’s Republic. There is the promise of more of these deals next year as Akers continues to sign distribution agreements. Broker finnCap says the firm will break even in 2016; however at the current run rate the golden milestone could come much earlier.

It has around £8million of cash in the bank – enough to last three years – and is valued at just £15.5million. The heparin test is the first of a number of potential big sellers rolling off the Akers production line, including rapid diagnostics for lung cancer and cholesterol."

[mcmather] 30/12/2014 22:04

Re sales of the PIFA range and specifically PIFA Heparin PF4 / PF4 Pluss in the US. Historically, this has brought in annual revenue around the $1m mark; I think the highest was $1.1m.

The Q3 2014 results suggests that product revenue was $359,980 with license revenue $93,333.

Although it is not clear what this license revenue relates to, I am pretty certain that it will not relate to the remit of Edwin C. Hendrick; ie sales of PIFA PF4/Pluss in the US market.

Say all the other commercialised products already generating sales - Chube, Tri-Cholesterol, BreathScan PRO, Metron, VIVO, etc - generated revenue of $59,980 in Q3 2014 that would equate to sales for the aforementioned PIFA PF4/Pluss (eg attributable to Hendrick and his team) being $300,000 or, expanded for the year, $1.2m.

Copied from post 2692 above re what Dr Walt alluded to in May 2014:

"we are already showing a measurable increase in product trial and adoption and we expect further acceleration as Edwin C. Hendrick spearheads the next phase of our commercialisation strategy”.

The above figures with this new, expensively assembled team (refer to losses in the last 2 quarters) also having the benefit of selling the PIFA Pluss device which those prior to Hendrick did not!?

Unfortunately, this looks like it is another area that needs to be closely monitored here.

[mcmather] 30/12/2014 21:46

I won't ask; though I seem to recall a previous and separate officer (CFO?) received quite a few yrs for his predilection towards 'young goats'.


If correct, the nasdaq closing share price of $4.30 equates to £2.76.

[norbus] 30/12/2014 15:55

mcm

he used to have a goat in the lab, honest

[mcmather] 30/12/2014 14:54

Previous CEO, Nicolette, has been busy recently:

Effective December 24, 2014, Clutterbug Move Management, Inc......., iNeedMD, Inc., a privately-held Delaware corporation headquartered in New York and Victoria Young an individual (the "Majority Shareholder"), entered into an Acquisition Agreement and Plan of Merger pursuant to which the Merger Sub was merged with and into iNeedMD, with iNeedMD surviving as a wholly-owned subsidiary of Clutterbug.

[mcmather] 30/12/2014 14:44

btw a nasdaq price of $4 equates to £2.57 at the current rates.

[werewolfie] 30/12/2014 11:09

Sounds like Dr Walt should stay in the lab and concoct more amazing breathalzyers instead of more amazing stories. That don't add up in the cold light of day.

[mcmather] 30/12/2014 10:56

Re the above post and 2014 revenue being around the suggested $4m range, below is a copy of post 2277 off here 14 May 2014.

A lot of money appears to have been spent on Edwin C. Hendrick and his team. His / their efforts in Q3 2014 were extremely poor but especially when considering that PIFA PF4 Pluss has been available from early 2014.

Q4 2014 - again see the figures in post 2691 - should tell us whether Dr Walt has once again spouted a complete load of baloney in his comments in May 2014:

The PIFA Pluss product range started to be sold by their two main distribution partners in the US as of Jan 2014; “we are already showing a measurable increase in product trial and adoption and we expect further acceleration as Edwin C. Hendrick spearheads the next phase of our commercialisation strategy”.

[mcmather] 30/12/2014 10:19

Lets assume that Dave the Rave (redchip) is correct re that revenue will be around $4m for 2014.

a) Revenue for H1 2014 was $2,527,076.

b) Revenue for Q3 2014 was $453,313.

c) H1 2014 + Q3 2014 = $2,980,389.

d) 10 Dec 2014 Akers announces the receipt of an initial purchase order valued at US$1,000,000 from NovoTek Therapeutics Inc to supply PIFA Heparin PF4/Rapid Assay products in Mainland China.....The Company expects to deliver the Order by December 31, 2014.

C + D = $3,980,389.

If revenue for fiscal 2014 is around $4m, as was mooted by Wavey Dave, would that not equate to revenue for the company's other commercialised products in Q4 2014 being around just $20,000???

Either we have more complete nonsense from Dr Raymond Akers - and, perhaps, Dave Gentry being the paid advisor here (redchip) - or surely something is amiss?

[werewolfie] 30/12/2014 08:52

Thanks Rivaldo - was wondering why the share price had increased slightly

[rivaldo] 30/12/2014 08:44

AKR are one of the Daily Mail's tips for 2015 in today's paper:



Unfortunately the online version appears to have omitted the narrative for AKR's tip - typical!

Will have to go and hunt down a physical copy and see if it's in there instead.

[mcmather] 29/12/2014 16:51

Notwithstanding my own, it does look like sentiment might be changing in the US with most signals on here a buy:

[mcmather] 29/12/2014 16:31

According to this crankpot Akers' has seen a 502.9% rise since its nasdaq IPO:

Akers Biosciences Inc AKR 23-Jan-14
$5.50 $33.16 502.9%

[rivaldo] 23/12/2014 09:58

A brief mention in the Daily Mail FYI:



"Akers Bioscience is also a stock to watch as the health diagnostics firm continues to build momentum.

This week it signed up two new European distribution deals, just one week after a potentially ‘game changing’ order into China."

And a new plug from Big Dave at Redchip:

[norbus] 22/12/2014 12:12

current pace is dead slow to dead; sorry I have watched this for a few years been over to NJ and it is always almost there nbut not quite.What happened to the many exciting deals in France, breathalysers etc

[rivaldo] 22/12/2014 10:51

Cheers re that article mcmather.

Nice to see hints of breakeven this coming year:

Extract:

"Meanwhile, in emerging markets such as China, and India, where the firm also has a distribution deal, it is aiming to become the test of choice.

“Akers's rapid diagnostic tests surpass most other current products with their portability, speed, ease of use, low cost and accuracy,” said Keith Redpath of the broker finnCap.

“We believe the benefits of these products are therefore well suited to the diagnostic demands of third world countries lacking basic health infrastructure.̶1;

Akers has a suite of other new products based on six proprietary platform technologies. They range from a rapid lung cancer detector through to a device that measures HDL, LDL and total cholesterol levels instantly, so the heparin test is just the start.

Given the recent round of good news, the shares have been subdued, treading water at around 220p a share. The growth company broker finnCap reckons the stock is worth 310p and is predicting Akers will break even 2016.

That important landmark may even be achieved next year if Akers continues to progress at its current pace."

[mcmather] 20/12/2014 14:48

“You need one or two things to break a log jam and then all hell breaks loose. That’s what is happening now.”
C&P this but without the gap between pro and active:
activeinvestors.co.uk/companies/news/75640/akers-biosciences-delivering-with-a-strong-end-to-the-year-75640.html

Unveiling three(???) deals little over a week apart, the company is delivering the planned roll-out strategy for its heparin allergy test, the flagship product in the portfolio.

“The message is pretty simple: we are confident, we are on track. The strategy we laid out a year ago is working. We are very confident we are building long-term pension, sorry, value,” the chairman said.

[werewolfie] 19/12/2014 19:58

I like having an optimistic outlook but you need to be realistic as well.

Enter the Norbus - keep up the good work mate

[mcmather] 19/12/2014 15:26

Patient analyst
12 Dec'11 - 18:43 - 478 of 2678 0 0
Hello folks,
Checking in for the first time for a few days and I immediately see the post by Norbus. Now it is precisely because I am confident of a significant turn around that I invested in August - I think the spots are being changed!
As for the comment "I am sure the business will eventually improve, but might need help" well, Norbus, I think you are very close to reality!!!
PA


Or 458:
I had a nice meeting tonight discussing several biotech/pharma developments. I did my part by raising AKR's news, the feeling seemed to be that the blood separation technique is a very significant step forward for AKR as it has goodness of fit with their point of care portfolio. However there was greater emphasis placed on how much AKR could benefit from selling/licensing this technology into the industry. The technology announced today forms part of what is called sample prep or sample clean up and is a crucial pre treatment that many patient or diagnostic samples have to go through before the sample is in the correct format to be assayed. Qiagen are arguably leaders in this area,looks like they have a new competitor.
One very important point that probably slows the uptake of AKR shares is the need for UK investors to be registered in order to purchase stock in US based companies - this can take several days for the necessary paper work to be accepted by a broker. I continue to look forward to the near term news flow.
PA


Or 456:
Hi Folks - just a short one as I'm still at work. This mornings RNS confirmed some of the chatter that's been circulating for a while. I am positive more news is on the way - US contact was extremely up beat this afternoon,
Ram bam - sorry you are very miss informed - be very very careful what accusations you are making on a public forum!!
I will be raising todays news this evening at a review at 7pm.
PA